According to Management, the highest ASPs has not been reflected in the quarter results announced earlier today.

 

New plant #12 has been fully commissioned (100%) in this quarter with installed capacity of 2.2 billion gloves.

 

Based on the basic assumption, we expect next quarter results to grow QoQ albeit at a lower pace.

 

Join our FREE telegram channel:

https://t.me/humbledinvestordiscussion

_________________________________________________________

 

All information provided here should be treated for informational purposes only. It is solely reflecting author's personal views and the author should not be held liable for any actions taken in reliance on information contained herein.

 

No buy call. No sell call. No bullshit. Only content.

 

PAT                              – RM43m (+782% YoY)

Gross profit margin      – 39%

PAT margin                  – 35%

Careplus Group has delivered stellar performance in Q3 2020 with historical high revenue and net profit ever achieved. This is beyond our expectation given that Careplus Group has sold 50% stake of its wholly owned subsidiary to Ansell.

Higher sales quantity, higher selling price, higher utilization rate and better capacity output leads to higher gloves sales in Q3 2020. If we look at the operation margin by comparing the preceding quarter, the EBITDA margin has increased from 23% to 38%, representing a surge of 15 percentage points which are due to better production efficiencies. This eventually also shows that the next quarter results for the comparable companies is expected to be as high as Careplus Group, and even higher expectation will be placed on the Big 4 in gloves sectors given their bigger market shares which are able to take on more orders at lower costs as a result of economies of scales.

But are there any one-off items to the Careplus Group’s results this quarter? In Q3 2020, the result was way beyond our expectations. Before we drilled into the actual performance of Careplus Group in Q3 2020, let’s go through the background of Careplus Group recent JV story.

Corporate Strategy

In May 2020, Careplus Group has entered into a JV agreement via the disposal of 50% stake in Careplus M to Ansell for RM27mil. This JV would result in Careplus Group losing control over Careplus M as wholly owned subsidiary and become a 50:50 joint venture company in Careplus Group.

The purchase consideration of RM27mil derived from “1.5x * 50% * Net assets” eventually indicating that Ansell is paying 75% of Careplus M’s net assets for 50% stake due to the 1.5x of net assets multiples (“NA multiples”).

The NA multiples of 1.5x has taken into consideration the trading multiples of other public listed comparable companies in Malaysia which operate in the same business segment as Careplus Group whose principal business activities are generated from the manufacturing of rubber gloves (“Comparable Companies”).

No.	Comparable Companies	Audited net assets (RM'000)	Market cap as at 31 Dec 2019 (RM'000)	Price to book ratio (x)
1	Comfort Gloves Berhad	277,856	460,530	1.66
2	HLT Global Berhad	47,900	92,156	1.92
3	Rubberex Corporation (M) Berhad	214,454	136,094	0.63
4	Supermax Corporation Berhad	1,123,710	1,807,169	1.61
			Average	1.46

As you can see, the NA multiples of 1.5x is within the low and high range and is close to the average P/B ratio of 1.46x which are computed based on the market capitalization as at 31 December 2019 and audited net assets as at 31 December 2018. If we were to compare against the lastest net assets and latest market capitalization, the NA multiples computed to be 10.4x (as shown below). In essence, we can deduce that the disposal of Careplus M favours more to Ansell rather than Careplus Group as Ansell is paying lesser compared to the current situation where the demand for gloves has never been so high before.

No.	Comparable Companies	Latest net assets (RM'000)	Market cap as at 25 Oct 2020 (RM'000)	Price to book ratio (x)
1	Comfort Gloves Berhad	369,830	2,506,681	6.78
2	HLT Global Berhad	82,822	981,088	11.85
3	Rubberex Corporation (M) Berhad	269,220	1,989,149	7.39
4	Supermax Corporation Berhad	1,608,423	25,214,400	15.68
			Average	10.42

From this disposal, Careplus Group would generate a cash inflow of RM27mil which is to be utilized as follows:

Descriptions	Proceeds (RM’000)	%
Careplus M subscription	10,500	39%
Capex	10,000	37%
Working capital	6,209	23%
Total	26,709	100%

The Careplus M subscription of RM10.5mil by Careplus Group will be discussed below as this involved another capital injection by Ansell of the same amount into Careplus M.

The capital expenditure of RM10mil will be used to increase Careplus Group’s annual installed capacity from 4.14 billion pieces (as at 31 Dec 2019) to 4.62 billion pieces. But are they (Careplus Group) doing the right decision to dispose the 50% stake?

Of course, the benefits of this disposal transaction to Careplus Group are as such:

• Extra cash for expansion by way of capex to introduce more production lines

• An opportunity to build a strategic alliance with Ansell Group, which is a global conglomerate involved in manufacturing of surgical and examination gloves and healthcare safety devices (able to leverage on Ansell Group’s market experience, knowledge and business alliances in the glove manufacturing industry)

• Able to grow the global portfolio of Careplus Group and increase market reach where Ansell group operates

Besides the disposal, another shareholders agreement was entered between both parties which includes a further subscription of new Careplus M shares in equal proportions at a collective consideration of RM21mil.

The JV company, Careplus M would have received RM10.5mil each (a total of RM21mil) from both Ansell and Careplus Group which are mainly used to partially settle the debts owing by Careplus M to Careplus Group.

Capital injection of RM21mil in Careplus M will be used as follows:

Descriptions	Proceeds (RM’000)	%
Settling interco transactions	12,000	57%
Capex	9,000	43%
Total	21,000	100%

Besides, 10% private placement has been announced in June 2020 whereby Careplus Group will raise new proceeds of RM11.43mil for capex expansion plans.

Financial Analysis

After the interco settlement, the liabilities would reduce and Careplus M would be ready for the new expansion ahead given their strong historical financials.

Financial Year	2016	2017	2018	2019	2020
No. of months	12M	12M	12M	12M	9M	12M Extrapolated
Careplus M	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Revenue	64,849	104,745	123,967	157,086	137,855	183,807
PAT	(8,299)	(7,047)	(6,308)	(1,849)	12,606	16,808
PAT margin (%)	-13%	-7%	-5%	-1%	9%	9%

From the table above, we can see that the historical net profit margin of Careplus M is improving. This is mainly due to the increase in production capacity arising from commissioning of new production lines.

To be more accurate in the financial performance analysis, let’s breakdown further the performance of Careplus M in FY2020 (during Covid times).

Careplus M – Joint Venture

Percentages of shareholdings		100%			50%
No. of months	Period	Revenue (RM’000)	Expenses (RM’000)	Profit (RM’000)	Profit (RM’000)	Profit margin (%)
4.5	1 January - 14 May 2020	63,000	(60,900)	2,100	N/A	3%
1.5	15 May - 30 June 2020	25,596	(23,824)	1,772	886	7%
3	1 July - 30 Sept 2020	49,259	(40,525)	8,734	4,367	18%
	Total	74,855	(64,349)	10,506	5,253	14%

From the analysis above, we can notice that the profit margin has actually increase exponentially during the last quarter from July to September 2020, achieving 18% net profit margin.

To compare like-to-like, assuming Careplus Group did not sell 50% stake in Careplus M to Ansell, the revenue would have actually increased by 104% YoY instead of 45% YoY and the net profit would have actually boosted by 851% YoY instead of 782% YoY.

Comparing to preceding quarter, if Careplus Group did not sell 50% stake in Careplus M to Ansell, total revenue would have increased by 19% YoY instead of 3% YoY and the net normalized profit would have increased by 118% YoY instead of 106% YoY. The comparison is shown in the figure below.

Careplus Group		Q3 2020	Q3 2019	Q2 2020
		RM'000	RM'000	RM'000
Revenue		122,705	84,339	118,898
Revenue - 100% Careplus M (assume did not sell)		49,259	-	25,596
Total revenue		171,964	84,339	144,494
% increase YoY			104%
% increase QoQ				19%
Net profit		42,856	(6,284)	36,212
Less: One-off gain		-	-	(15,400)
Profit - 50% JV (assume did not sell)		4,367	-	886
Total profit		47,223	(6,284)	21,698
% increase YoY			851%
% increase QoQ				118%
Net profit margin %		27%		15%

Conclusion

The BIG question left, is whether Careplus Group can continue to grow QoQ? It is hard to gauge the supply and demand for gloves, but what we can see is that all gloves companies are expanding their capacity which will then increase the market supply. If the demand could not catch up, demand supply imbalance will result in price competition in order to lower down inventory level for respective companies.

We can observe that the production capacity of Careplus Group has increased from 4.14 billion pieces in Q3 2019 to 4.62 billion pieces of gloves in Q3 2020, an increase of 12% YoY. The demand for gloves is definitely more than 12% comparing year-on-year. Before the supply of additional 4 and 15 production lines kick in by end of 2020 and 2021 which will increase the annual capacity to 10.5 billion gloves (an increase of 127% in the span of 1.5 years), we believe the next quarter results would still be able to deliver a YoY and QoQ growth (given the third wave of Covid-19 situation) albeit at a slower pace.

But bear in mind that share price nowadays is moving 6 months ahead of results and lucrative business will always attract competition. With vaccine expected to be available by early next year, the demand for glove may peak by end of this year. Hence, the upside may be limited with the potential huge supply coming into the market.

____________________________________________________________________________________

All information provided here should be treated for informational and educational purposes only. It is solely reflecting author's personal views and the author should not be held liable for any actions taken in reliance on information contained herein. No buy call. No sell call. No bullshit. Only content.

If you think the article / information is useful to you and you want to learn more, you are welcomed to join our FREE telegram channel @Humbled Investor Discussion or t.me/humbledinvestordiscussion.

This article was written on 25.10.2020.

Mi Technovation - The risk of setting up a new plant

 

However, from the start of our coverage on Mi (24 May), the share price has sky-rocket from RM2.38 to RM4.68 (+97%). This is contributed by the strong growth prospect from the new factory and high margin business despite the risks of running a new factory which is discussed in the slides above.

 

You may refer to here for Mi's business overview (with competitive advantages explained) and why I did not invest in Mi last year.

https://humbledinvestor.blogspot.com/2020/05/mi-technovation-why-i-did-not-invest-in.html?fbclid=IwAR2-Xc2i04KBQLbPl5HHGLmb_GxHgjFSzR3QDFLgrFKWb76_GLR91Mqi7VE

 

Follow us and don't forget to share this to your friends!

_________________________________________________________

 

All information provided here should be treated for informational purposes only. It is solely reflecting author's personal views and the author should not be held liable for any actions taken in reliance on information contained herein.

 

No buy call. No sell call. No bullshit. Only content.

 

If you think the article / information is useful to you, you can <SHARE> this article and support us by <LIKE> and <FOLLOW> our Facebook page "Humbled Investor". Thank you so much for supporting.

 

[DO NOT FALL INTO THE TRAP - ESCERAM]

 

Today 14 October 2020 is the ex-date for ESCERAM's 1-for-1 bonus issue and 1-for-1 free warrant.

 

Normally, bonus issue entitlement date is only T+2 where after 2 days and you would be entitled for the shares. However since this is a bonus issue with free warrant, the listing date has been delayed far off to 26 October 2020 (as announced in 2 October 2020 announcement) which is rare. Although your entitlement date is 15 October 2020, the bonus shares that are available to trade shall be  on 26 October 2020 which is the available/listing date.

 

Imagine if you owned 100 ESCERAM shares yesterday and you saw the share price went up high today, you might consider selling 200 shares today since you know the share price has already been adjusted downwards and the shares you owned technically is 200.  You contacted your broker/remisier to sell your 200 shares.

 

And normally, there is T+2 payment terms for each transaction you made if you are not using cash upfront.

 

What you might fail to notice is that the additional 100 free bonus shares has not yet been credited into your account until 26 October 2020 (which is more than 7 trading days). And hence, this is considered as short selling. Short selling is a fairly simple concept—an investor borrows a stock, sells the stock, and then buys the stock back to return it to the lender. Short sellers are betting that the stock they sell will drop in price.

 

However, normally the additional 100 bonus shares would be credited into your account within T+2 and therefore you could still buy back the shares that you have short-sell. But in this case, at the end of T+2, you only have 100 shares and you ended up selling 200 shares. Now you are lacking 100 shares to payback. 

 

Now, under Bursa regulation, since you do not have enough shares to settle, you would have to buy-in. Buying-in is the process of buying shares by Bursa Malaysia for settlement for failed trades on behalf of defaulters. Bursa Malaysia shall institute buying-in against the relevant selling POs on the settlement day of the contract, in event that the selling clients' CDS accounts do not have sufficient securities for settlement on due date.

 

The important thing is the price that you paid for buying-in is higher than the market price. The bidding price for buying-in is 10 ticks above the closing price of the previous trading day. If the closing price for tomorrow is 90 sen, the bidding price that you are required to buy-in would be RM0.95 of the quantity you bought which is 10x additional of your tick size (tick size below RM1 is 0.5sen, hence 10 x 0.05 = RM0.50 extra). This is the cost for ignorance.

 

At the end of the day, clearly there are manipulators behind this who goreng up the share price and invite the ignorant investors to sell their shares. The investors who do not know this would have to ended up buying-in at a higher bid price.

 

Hence, advice here is to do your own research before buying or selling.

 

Share this to your friends and families to prevent them from falling into the trap next time. Learn up this lesson so that you and your friends wont make/repeat the mistake in the future (again).

 

P/S: If you think in reverse psychology, tomorrow might possibly open high and close higher than today's closing. No buy sell recommendation, trade at your own risks.

 

_____________________

 

All information provided here should be treated for informational purposes only. It is solely reflecting author's personal views and the author should not be held liable for any actions taken in reliance on information contained herein.

 

No buy call. No sell call. No bullshit. Only content.

 

If you think the article / information is useful to you, you can this article and support us by and our Facebook page "Humbled Investor". Thank you so much for supporting.

 

[Mr DIY IPO] Do you know what is the intention for the promoters to sell their shares (offer for sales) amounting to 80% out of the total shares being offered to the public?

 

Would you invest into a PE 31x retail company at this kind of environment where some businesses are barely surviving?

 

Let us know your thoughts at the comments below! Happy to discuss.

_________________________________________________________

 

All information provided here should be treated for informational purposes only. It is solely reflecting author's personal views and the author should not be held liable for any actions taken in reliance on information contained herein.

 

No buy call. No sell call. No bullshit. Only content.

 

If you think the article / information is useful to you, you can <SHARE> this article and support us by <LIKE> and <FOLLOW> our Facebook page "Humbled Investor". Thank you so much for supporting.

 

 

[Samaiden IPO ends at 5pm Tomorrow!] Not everyone will tell you, but these are the things you should know before it's too late!

 

Should you subscribe the IPO?

_________________________________________________________

 

All information provided here should be treated for informational purposes only. It is solely reflecting author's personal views and the author should not be held liable for any actions taken in reliance on information contained herein.

 

No buy call. No sell call. No bullshit. Only content.

 

If you think the article / information is useful to you, you can this article and support us by and our Facebook page "Humbled Investor". Thank you so much for supporting.